FabRx’s latest innovation of 3D printed pellets (Miniprintlets) published in Pharmaceutics

April 03, 2019 | News

As a world first, FabRx have applied their innovative 3D printing technology for the production of pellets (Miniprintlets). The study details the capability for selective laser sintering (SLS) to produce small oral dosage forms (1mm and 2mm in diameter) containing multiple active ingredients (paracetamol and ibuprofen) in a single step process. The researchers found that by changing the excipients included in the formulations, drug release could be modulated from immediate through to modified release profiles. FabRx’s latest innovation on 3D printing pellets has been published in Pharmaceutics, which you can access here.

Paper abstract: Selective laser sintering (SLS) is a single-step three-dimensional printing (3DP) process that can be leveraged to engineer a wide array of drug delivery systems. The aim of this work was to utilise SLS 3DP, for the first time, to produce small oral dosage forms with modified release properties. As such, paracetamol-loaded 3D printed multiparticulates, termed miniprintlets, were fabricated in 1 mm and 2 mm diameters. Despite their large surface area compared with a conventional monolithic tablet, the ethyl cellulose-based miniprintlets exhibited prolonged drug release patterns. The possibility of producing miniprintlets combining two drugs, namely paracetamol and ibuprofen, was also investigated. By varying the polymer, the dual miniprintlets were programmed to achieve customised drug release patterns, whereby one drug was released immediately from a Kollicoat Instant Release matrix, whilst the effect of the second drug was sustained over an extended time span using ethyl cellulose. Herein, this work has highlighted the versatility of SLS 3DP to fabricate small and intricate formulations containing multiple active pharmaceutical ingredients with distinct release properties.

 

 

Back to News

Copyright © 2018 FabRx Ltd